ArticleBMC cancer2026
Long-term outcomes and anorectal functional status of patients with anal squamous cell carcinoma treated with the modern technique of intensity-modulated radiotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundIntensity-modulated radiation therapy (IMRT) may reduce mortality in patients with squamous cell carcinoma of the anus (SCCA), but there are limited data in long-term outcomes. This study reported 5-year outcomes in SCCA patients treated with IMRT-based definitive chemoradiation.
methodsSixty-five consecutive patients with T1-4N0-3M0 SCCA treated with IMRT-based concurrent chemoradiation (CCRT) from Jan 1, 2010, were retrospectively reviewed. Treatment outcomes included overall survival (OS), disease-free survival (DFS), anal cancer-specific mortality (ACSM), local-regional failure (LRF), distant metastasis (DM) and colostomy failure (CF), late toxicity and anorectal function.
resultsThe patients had a median age of 52 years; 70.8% were female, 30.8% had T3-4 lesions, and 46.2% were clinically node positive. The median radiation doses to the gross tumor volume of the anus (GTVA) was 54 Gy (with a median BED10 of 65.7 Gy). The 5-year OS and DFS rates were 82.4% and 74.6%, respectively. The 5-year rates of ACSM, LRF, DM and CF were 13.9%, 18.0%, 6.5% and 19.0%, respectively. Patients treated with BED10 > 66 Gy exhibited inferior DFS and OS. The most common grade 3 late AEs were gastrointestinal (6.2%). The median Wexner score and Vaizey score were 0 and 2, respectively. The median LARS score was 0, with 3 patients reporting minor LARS.
conclusionIMRT-based CCRT can achieve excellent long-term local control with manageable late toxicity in patients with locoregional SCCA. Anorectal function in long-term survivors was acceptable. Given different tumor burden, findings regarding radiation dose escalation beyond a BED10 of 66 Gy should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.